Thiazolidinediones: A pharmacological overview

Clinical Drug Investigation

Volumn 22, Issue 8, 2002, Pages 485-505

  Owens, David R ^a,b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ACARBOSE; BEZAFIBRATE; CLOFIBRATE; COLESTYRAMINE; CYCLOSPORIN; DIGOXIN; FATTY ACID; FENOFIBRATE; GLIBENCLAMIDE; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENPROCOUMON; PIOGLITAZONE; REGLITAZAR; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TERFENADINE; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE; UNINDEXED DRUG; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR RISK; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER TOXICITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0036053172     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222080-00001     Document Type: Review

References (118)

1. Role of insulin resistance in human disease
2. Insulin resistance: The fundamental trigger of type 2 diabetes
3. Insulin resistance and human disease: A short history
4. Thiazolidinediones: The new insulin enhancers
5. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β and -γ in the adult rat
6. Rosiglitazone (BRL 49653), a PPARγ-selective agonist, causes peroxisome proliferator-like liver effects in obese mice
7. PPAR-γ agonists: Therapeutic role in diabetes, inflammation and cancer
8. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
9. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
10. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative
11. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
12. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers
13. Effect of thiazolidinediones on expression of UCP2 and adipocyte markers in human PAZ6 adipocytes
14. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability
15. Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes
16. Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocyte differentiation
17. Induction of uncoupling protein in brown adipose tissue: Synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent
18. Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells
19. Enhancement of adipocyte differentiation by an insulin-sensitizing agent
20. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells
21. The short- and long-term effects of tumor necrosis factor-α and BRL 49653 on peroxisome proliferator-activated receptor (PPAR)γ gene expression and other adipocyte genes
22. Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats
23. Adipocyte fatty acid-binding protein: Regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent
24. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat
25. In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice
26. Insulin sensitization in diabetic rat liver by an antihyperglycemic agent
27. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with rosiglitazone (BRL 49653) in human adipocytes
28. Effect of rosiglitazone on the differential expression of diabetes associated proteins in pancreatic islets of C57BI/6J lep/lep mice
29. The PPARs: From orphan receptors to drug discovery
30. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents
31. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone
32. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects
33. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARγ in endothelial function
34. Expression and function of PPARγ in rat and human vascular smooth muscle cells
35. Pioglitazone attenuates hypertension and inhibits growth in renal arteriolar smooth muscle in rats
36. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism
37. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone
38. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression
39. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals
40. Rosiglitazone plus β3-adrenoceptor agonist treatment normalizes glycaemia in C57BI/KsJ db/db mice
41. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling
42. Effects of pioglitazone on glucose and lipid metabolism in Wistar Fatty rats
43. Antidiabetic actions of insulin sensitizer alone or in combination with α-glucosidase inhibitor in genetically obese-diabetic rats, Wistar Fatty
44. Lipid abnormalities in tissues of the KKAy mouse: Effects of pioglitazone on malonyl-CoA and diacylglycerol
45. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant Rhesus monkeys
46. Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine
47. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus
48. A review of rosiglitazone in type 2 diabetes mellitus
49. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT
50. Rosiglitazone modulates glucose metabolism in IRS-2 knockout mice
51. Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats
52. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
53. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes
54. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients
55. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells
56. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells
57. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator: Activated receptor-gamma
58. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase
59. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats
60. Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb
61. Insulin-sensitizing effect of rosiglitazone by regulation of glucose transporters in muscle and fat of Zucker rats
62. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance
63. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar Fatty rats
64. Therapeutic index for rosiglitazone in dietary obese rats: Separation of efficacy and haemodilution
65. Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes
66. Pioglitazone treated for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle plasma membranes
67. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats
68. A comparison in a clinical setting of the efficacy and side effects of the three thiazolidinediones
69. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus a retrospective review of randomly selected medical records
70. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone
71. Effects of glucose and weight reduction on lipid clearance: Animal aspect
72. In vivo free fatty acid utilization in individual tissues of lean, obese and obese rosiglitazone treated Zucker rats
73. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
74. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat
75. Rosiglitazone treatment reduces gamma-glutamyltransferase levels, a marker for visceral and hepatic fat
76. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects
77. Pioglitazone monotherapy reduces atherogenic index of plasma (AIP), an indirect indicator of LDL particle size, in patients with type 2 diabetes
78. Blood pressure lowering by pioglitazone: Evidence for a direct vascular effect
79. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats
80. Pioglitazone suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK coupling with Pyk2
81. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats
82. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats
83. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
84. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes
85. Diabetes and cardiovascular disease: The "common soil" hypothesis
86. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): Relation to reduced foetal growth
87. The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome
88. Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats
89. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus
90. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
91. Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat
92. Peroxisome proliferator-activated receptor agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats
93. Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats
94. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro
95. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes
96. Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima Fatty rats
97. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertension
98. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
99. Pioglitazone reduces blood pressure in patients with type-2-diabetes mellitus
100. Rosiglitazone
101. Troglitazone: A review of its use in the management of type 2 diabetes mellitus
102. Clinical pharmacokinetics of pioglitazone
103. Disposition of the new antidiabetic agent pioglitazone in rats, dogs and monkeys
104. Absorption, disposition and metabolism or rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans
105. Systemic exposure to rosiglitazone is unaltered by food
106. Effect of food on the pharmacokinetics of pioglitazone
107. Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food
108. Clinical pharmacokinetics of troglitazone
109. Pioglitazone does not markedly alter oral contraceptive or hormone replacement therapy pharmacokinetics
110. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: Comparison with pioglitazone and rosiglitazone
111. Pharmacokinetics of pioglitazone in patients with renal impairment
112. Effect of renal impairment on the pharmacokinetics of rosiglitazone
113. Effect of hepatic impairment on the pharmacokinetics of rosiglitazone
114. Thiazolidinedione hepatotoxicity: A class effect?
115. Thiazolidinediones: An update
116. Rosiglitazone monotherapy is effective in patients with type 2 diabetes
117. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with Type 2 diabetes metlitus: A randomised placebo-controlled study
118. Rosiglitazone liver safety update